Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Onconova Therapeutics Announces Closing of Public Offering of Common Stock
April 26, 2017 17:25 ET
|
Onconova Therapeutics
NEWTOWN, Pa., April 26, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug...
Kura Oncology Granted U.S. Patent for Clinical-Stage ERK Inhibitor, KO-947
April 19, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., April 19, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Doses First Patient in Phase 1 Trial of ERK Inhibitor KO-947
April 07, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., April 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947 and KO-539
April 05, 2017 08:00 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., April 05, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS
March 31, 2017 07:05 ET
|
FibroGen, Inc.
SAN FRANCISCO, March 31, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced the approval by the China Food and Drug Administration...
Preclinical Data for Kura Oncology Development Compounds to be Presented at AACR Annual Meeting 2017
March 29, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines, today announced...
Kura Oncology Reports Fourth Quarter and Full Year 2016 Operational and Financial Results
March 14, 2017 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., March 14, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (NASDAQ:KURA) a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology to Report Fourth Quarter and Full Year 2016 Financial Results
March 07, 2017 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Reports Updated Clinical Activity Data in Ongoing Phase 2 Trial for Tipifarnib
March 06, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Announces Presentation of Preliminary Clinical Data for Tipifarnib in HRAS Mutant Squamous Cell Carcinomas of the Head and Neck at TAT 2017
February 27, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced an oral presentation for its lead product...